🇺🇸 FDA

Company profile · Sponsor

Kymera

Kymera Therapeutics

KYMR · NYSE biotech WATERTOWN, MA, USA
Pipeline
12
Drugs
0
Patents
8

Quick answer

Kymera (KYMR) is a biotech company. headquartered in WATERTOWN, MA, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker KYMR
Exchange NYSE
Company type biotech
Headquarters WATERTOWN, MA, USA
SEC CIK 0001815442

Pipeline (12)

Search pipeline →

  1. KT-621

    Kymera

    Atopic Dermatitis

    phase 2 small molecule active

    2 trials

  2. KT-621

    Kymera

    Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  3. KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.

    Kymera

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  4. KT-621, Placebo oral tablet matched to KT-621, KT-621, KT-621

    Kymera

    Uncontrolled Moderate to Severe Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  5. SAR444656 (KT-474)

    Kymera

    Hidradenitis Suppurativa

    phase 2 small molecule terminated

    1 trial

  6. SAR444656 (KT-474)

    Kymera

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  7. KT-253

    Kymera

    Myeloid Malignancies

    phase 1 small molecule completed

    1 trial

  8. KT-333

    Kymera

    Non Hodgkin Lymphoma (NHL)

    phase 1 small molecule completed

    1 trial

  9. KT-413

    Kymera

    Non Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  10. KT-474/Placebo

    Kymera

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  11. KT-579

    Kymera

    Healthy Participants

    phase 1 small molecule active

    1 trial

  12. KT-621

    Kymera

    Healthy Participants Study

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12258341

    IRAK degraders and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12187744

    IRAK4 degraders and synthesis thereof

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12171768

    IRAK4 degraders and uses thereof

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12168057

    IRAK degraders and uses thereof

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12150995

    IRAK degraders and uses thereof

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12097261

    CDK2 degraders and uses thereof

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12091411

    IRAK degraders and uses thereof

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12077555

    STAT degraders and uses thereof

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Kymera?

Kymera (KYMR) is a biotech company. headquartered in WATERTOWN, MA, USA. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Kymera sponsor?

We track 12 ClinicalTrials.gov-linked programs for Kymera, including KT-621 and 11 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Kymera company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.